Navigation Links
Isis Pharmaceuticals to Present at Goldman Sachs' 30th Annual Global Healthcare Conference
Date:6/4/2009

CARLSBAD, Calif., June 4 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. (Nasdaq: ISIS), the leader in antisense therapeutics, today announced that management will present a company overview at the Goldman Sachs 30th Annual Global Healthcare Conference on Wednesday, June 10, 2009, at 4:30 p.m. ET at the Grand Hyatt Hotel in New York City.

A live audio webcast of the presentation will be available on the "Investor Center" section of the Company's Web site, www.isispharm.com. A replay of the presentation will be available on the Isis Web site within 48 hours and will be archived for a limited time.

About Isis Pharmaceuticals, Inc.

Isis is exploiting its expertise in RNA to discover and develop novel drugs for its product pipeline and for its partners. The Company has successfully commercialized the world's first antisense drug and has 19 drugs in development. Isis' drug development programs are focused on treating cardiovascular and metabolic diseases. Isis' partners are developing antisense drugs invented by Isis to treat a wide variety of diseases. Isis and Alnylam Pharmaceuticals are joint owners of Regulus Therapeutics Inc., a company focused on the discovery, development and commercialization of microRNA therapeutics. Isis also has made significant innovations beyond human therapeutics resulting in products that other companies, including Abbott, are commercializing. As an innovator in RNA-based drug discovery and development, Isis is the owner or exclusive licensee of over 1,600 issued patents worldwide. Additional information about Isis is available at www.isispharm.com.


'/>"/>
SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/23/2016)... ... May 23, 2016 , ... ... and sexual objectification, according to Georgia State University researchers. , In ... in the fifth, sixth and seventh grades shared their experiences with strained ...
(Date:5/23/2016)... ... May 23, 2016 , ... Cosmetic Town, an ... about cosmetic procedures, began updating their library of over 300 encyclopedic medical articles. ... articles in order to feature the latest breakthroughs in plastic surgery procedures since ...
(Date:5/23/2016)... WASHINGTON, D.C. (PRWEB) , ... May 23, 2016 , ... ... Phyllis Greenberger, MSW, has decided to move on from that role. , “No one ... years as did Phyllis Greenberger,” said SWHR Founder Florence Haseltine, MD, PhD. “We offer ...
(Date:5/23/2016)... ... 2016 , ... In Pursuit of Balance (IPOB) co-founders Jasmine Hirsch and Rajat ... the end of 2016. , “We created IPOB to change the dialogue around ... back on what we have achieved, we’re gratified by the response of wine producers, ...
(Date:5/23/2016)... ... May 23, 2016 , ... Four Circles Recovery Center, a ... is proud to announce the launch of its new extended care program, Fifth Circle. ... treatment at Four Circles or another primary treatment program, Fifth Circle is designed to ...
Breaking Medicine News(10 mins):
(Date:5/22/2016)... , May 23, 2016 ... develop its anti-fibrotic and anti-inflammatory compound DS102 in ... as in non-alcoholic steatohepatitis (NASH) patients. ... significantly sequestered in lung tissue and has bronchodilatory, ... after oral administration. The Company will publish further ...
(Date:5/20/2016)... May 20, 2016 - ... Technologies, Insulins, Growth Hormones, Recombinant Coagulation Factors and ... - This New Study Reveals Selling Opportunities and ... ,What is the future of biologics, ... technological and commercial analysis. Staying ahead in data ...
(Date:5/19/2016)... 19, 2016  According to the World Health ... lacks basic diagnostic imaging. Whereas mammography or X-ray ... United States , many places around the ... fact, the WHO reports that those approximately 4 ... treatable death, simply due to the unavailability of ...
Breaking Medicine Technology: